Chicago-based Rosalind Franklin University of Medicine and Science (RFU) and Aptinyx, a US-based clinical-stage biopharmaceutical company, have entered into a research collaboration to support the development of new therapeutics for brain and central nervous system disorders, it was reported on Wednesday.
RFU's Brain Science Institute aims to identify and solve fundamental aspects of brain function and development and utilise those findings to understand the mechanisms of brain diseases. Under a recently executed research agreement, investigators within the institute will partner with Evanston-based Aptinyx, which is developing novel therapies for neurologic disorders including chronic pain, post-traumatic stress disorder and cognitive impairment.
Amiel Rosenkranz, PhD, director of the Brain Science Institute, said, 'This is an exciting opportunity for neuroscientists at RFU to contribute to the advancement of novel treatments for difficult-to-treat disorders. We are grateful to be working with Aptinyx on their promising therapeutics.'
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials